A groundbreaking scientific investigation has illuminated a key biological mechanism through which regular physical exertion serves as a potent protector of cognitive function, potentially offering novel avenues for combating age-related memory loss and neurodegenerative diseases like Alzheimer’s. Researchers at the University of California, San Francisco (UCSF) have identified a crucial enzymatic pathway that explains the observed enhancements in thinking and memory associated with exercise, suggesting that physical activity bolsters the brain’s inherent protective systems, thereby safeguarding it from the cumulative damage of aging.
The aging process inevitably impacts the integrity of the blood-brain barrier, a sophisticated and highly selective vascular network that acts as a vital guardian, meticulously shielding the delicate neural tissue from potentially harmful substances circulating within the systemic bloodstream. Over time, this intricate barrier can gradually lose its robustness, becoming increasingly permeable and allowing the ingress of detrimental compounds. This compromised state can precipitate neuroinflammation, a significant contributing factor to cognitive deterioration and a hallmark pathological feature observed in various neurological conditions, most notably Alzheimer’s disease.
Previous research conducted by this UCSF team had previously established a correlation between physical activity and elevated levels of a specific enzyme, GPLD1, produced by the liver in exercising laboratory mice. This enzyme appeared to possess rejuvenating properties for the brain, but a significant puzzle remained: GPLD1 itself is incapable of crossing the blood-brain barrier, leaving scientists perplexed as to how it could possibly exert its beneficial cognitive effects. The recent study now provides a compelling resolution to this long-standing mystery.
The core of the new findings centers on the intricate interplay between GPLD1 and another protein, known as TNAP. As organisms age, TNAP demonstrably accumulates on the surface of cells that constitute the blood-brain barrier. This buildup directly contributes to the weakening of the barrier and an increase in its permeability. However, the introduction of exercise triggers a remarkable cascade: the liver, stimulated by physical activity, releases GPLD1 into the bloodstream. This circulating enzyme then navigates its way to the blood vessels surrounding the brain, where it performs a critical function by cleaving or removing TNAP from the cellular membranes. This enzymatic action effectively helps to restore the structural integrity and protective capabilities of the blood-brain barrier.
Dr. Saul Villeda, an associate director at the UCSF Bakar Aging Research Institute and senior author of the study, emphasized the profound interconnectedness between systemic bodily functions and brain aging. "This discovery underscores the critical relevance of the body’s overall health in understanding the processes that lead to cognitive decline with age," he remarked, highlighting the study’s publication in the esteemed journal Cell.
To meticulously dissect how GPLD1 achieves its protective effects, the research team concentrated on the enzyme’s well-established enzymatic prowess: its ability to cleave specific protein targets from cell surfaces. The scientists embarked on a systematic search for tissues rich in proteins that could serve as potential targets for GPLD1, with a particular focus on proteins that might accumulate with advancing age. The cells forming the blood-brain barrier emerged as particularly compelling candidates due to their possession of several proteins that were plausible substrates for GPLD1. Through rigorous laboratory testing, a single protein, TNAP, was identified as the sole target that was effectively processed by GPLD1.
Further experimentation solidified the pivotal role of TNAP in the context of cognitive decline. When young mice were genetically engineered to overexpress TNAP within their blood-brain barrier cells, they exhibited memory deficits and cognitive impairments that were strikingly similar to those observed in older, untreated animals. Conversely, when researchers intervened to reduce TNAP levels in 2-year-old mice – an age equivalent to approximately 70 human years – a discernible improvement was noted. The blood-brain barrier became less permeable, inflammatory markers within the brain decreased, and these aged mice demonstrated enhanced performance on memory-related tasks.
Dr. Gregor Bieri, a postdoctoral scholar in Dr. Villeda’s lab and a co-first author of the study, expressed his optimism regarding the timing of intervention. "We were able to tap into this mechanism late in life, for the mice, and it still worked," he stated, indicating the potential for therapeutic strategies even in later stages of aging.
The implications of these findings for the understanding and treatment of Alzheimer’s disease and the broader spectrum of brain aging are substantial. The research strongly suggests that the development of pharmacological agents capable of targeting and trimming proteins like TNAP could represent a novel therapeutic strategy. Such interventions could potentially restore the compromised blood-brain barrier, offering a protective effect even after its structural integrity has been significantly weakened by the aging process.
Dr. Villeda pointed out the overlooked biological pathways in current Alzheimer’s research. "We’re uncovering biology that Alzheimer’s research has largely overlooked," he explained. "It may open new therapeutic possibilities beyond the traditional strategies that focus almost exclusively on the brain," he added, emphasizing the potential of a more holistic, systemic approach.
The collaborative effort involved a comprehensive team of UCSF researchers, including Karishma Pratt, Yasuhiro Fuseya, Turan Aghayev, Juliana Sucharov, Alana Horowitz, Amber Philp, Karla Fonseca-Valencia, Rebecca Chu, Mason Phan, Laura Remesal, Andrew Yang, and Kaitlin Casaletto, all contributing to the comprehensive study. The research was generously supported by grants from various esteemed institutions, including the National Institutes of Health (with specific grant numbers AG081038, AG086042, AG082414, AG077770, AG067740, and P30 DK063720), the Simons Foundation, the Bakar Family Foundation, the Cure Alzheimer’s Fund, the Hillblom Foundation, the Glenn Foundation, the Japan Society for the Promotion of Science (JSPS), the Japanese Biochemistry Postdoctoral Fellowship, the Multiple Sclerosis Foundation, Frontiers in Medical Research, the American Federation for Aging Research, the National Science Foundation, the Bakar Aging Research Institute, and significant contributions from Marc and Lynne Benioff.
About the Author
